Short Interest: What’s Ahead for Cumberland Pharmaceuticals Incorporated (NASDAQ:CPIX) After More Shorted Shares?

November 30, 2016 - By Pete Kolinski   ·   0 Comments

Short Interest: What’s Ahead for Cumberland Pharmaceuticals Incorporated (NASDAQ:CPIX) After More Shorted Shares?

The stock of Cumberland Pharmaceuticals Incorporated (NASDAQ:CPIX) registered an increase of 12.67% in short interest. CPIX’s total short interest was 65,800 shares in November as published by FINRA. Its up 12.67% from 58,400 shares, reported previously. With 13,000 shares average volume, it will take short sellers 5 days to cover their CPIX’s short positions. The short interest to Cumberland Pharmaceuticals Incorporated’s float is 0.66%. The stock decreased 0.18% or $0.01 on November 29, hitting $5.54. Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) has risen 17.87% since April 27, 2016 and is uptrending. It has outperformed by 12.65% the S&P500.

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The company has a market cap of $89.64 million. The Firm is focused on the acquisition, development and commercialization of branded prescription products. It currently has negative earnings. The Firm operates through specialty pharmaceutical products segment.

Insitutional Activity: The institutional sentiment decreased to 0.65 in Q2 2016. Its down 0.17, from 0.82 in 2016Q1. The ratio turned negative, as 7 funds sold all Cumberland Pharmaceuticals, Inc. shares owned while 10 reduced positions. 3 funds bought stakes while 11 increased positions. They now own 5.11 million shares or 2.07% less from 5.21 million shares in 2016Q1.
Bancorp Of America De has 0% invested in the company for 49 shares. Bridgeway Cap Management, a Texas-based fund reported 277,300 shares. Dimensional Fund Lp last reported 0% of its portfolio in the stock. Cambridge Investment Research holds 0% or 10,000 shares in its portfolio. Eagle Global Advsr Lc holds 0.01% or 83,535 shares in its portfolio. Renaissance Limited Liability Company, a New York-based fund reported 235,300 shares. Vanguard Group accumulated 297,223 shares or 0% of the stock. Sei Invs accumulated 254 shares or 0% of the stock. Delta Asset Ltd Company Tn holds 0.01% of its portfolio in Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) for 12,000 shares. Blackrock Inv Mngmt Limited Liability holds 0% or 1,900 shares in its portfolio. Jacobs Levy Equity Inc has 14,050 shares for 0% of their US portfolio. Morgan Stanley accumulated 37,513 shares or 0% of the stock. Moreover, Jw Asset Mgmt Ltd Limited Liability Company has 0.04% invested in Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) for 10,939 shares. Citadel Advsr Limited Liability Company owns 12,895 shares or 0% of their US portfolio. Fincl Bank Of New York Mellon holds 0% or 21,334 shares in its portfolio.

Insider Transactions: Since August 17, 2016, the stock had 1 insider purchase, and 2 insider sales for $103,152 net activity. 900 shares with value of $4,950 were bought by Bonner Michael on Thursday, November 17. $94,302 worth of Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) was sold by Lawrence Thomas R on Tuesday, November 15.

CPIX Company Profile

Cumberland Pharmaceuticals Inc. (Cumberland), incorporated on January 7, 1999, is a specialty pharmaceutical company. The Firm is focused on the acquisition, development and commercialization of branded prescription products. The Firm operates through specialty pharmaceutical products segment. The Company’s target markets are hospital acute care and gastroenterology. The Firm markets and sells its approved products through its hospital and gastroenterology sales forces in the United States. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection; Caldolor (ibuprofen) Injection; Kristalose (lactulose) for Oral Solution; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin); Vaprisol (conivaptan) Injection; Hepatoren (ifetroban) Injection, and Boxaban (ifetroban) oral capsules.

More notable recent Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) news were published by: Marketwatch.com which released: “Cumberland Pharmaceuticals Inc.” on December 21, 2009, also Prnewswire.com with their article: “Cumberland Pharmaceuticals Begins U.S. Shipments Of Ethyol® (amifostine) For …” published on August 23, 2016, Prnewswire.com published: “Cumberland Pharmaceuticals Reports Third Quarter & Year To Date 2016 Financial …” on November 01, 2016. More interesting news about Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) were released by: Prnewswire.com and their article: “Cumberland Pharmaceuticals Reports Second Quarter 2016 Financial Results” published on August 02, 2016 as well as Prnewswire.com‘s news article titled: “Cumberland Pharmaceuticals Announces New Program To Develop Portabanâ„¢ For …” with publication date: September 14, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Pete Kolinski

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>